--- title: "JingTai Technology and YaoTang Bio have reached a collaboration for the innovative research and development of AI messenger mRNA drugs" type: "News" locale: "en" url: "https://longbridge.com/en/news/276559202.md" description: "JingTai Technology has reached a collaboration with YaoTang Bio to innovate and develop AI messenger mRNA drugs, focusing on mRNA drugs and CAR-T therapies, and building an AI-driven mRNA experimental screening platform. The two parties will integrate AI predictive design with experimental validation to improve research and development efficiency and success rates, optimizing the expression efficiency and stability of mRNA sequences. It is expected that this platform can be expanded to more complex disease application scenarios" datetime: "2026-02-23T03:06:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276559202.md) - [en](https://longbridge.com/en/news/276559202.md) - [zh-HK](https://longbridge.com/zh-HK/news/276559202.md) --- # JingTai Technology and YaoTang Bio have reached a collaboration for the innovative research and development of AI messenger mRNA drugs JingTai Technology (02228.HK) announced a collaboration with YaoTang Shanghai Biotechnology to innovate in the research and development of AI messenger RNA (mRNA) drugs. Both parties will focus on the fields of mRNA drugs and CAR-T therapies, jointly building an AI-driven mRNA dry and wet lab closed-loop screening platform to accelerate the emergence of breakthrough therapies. JingTai Technology stated that its AI predictive design "dry lab" will deeply integrate with YaoTang Biotechnology's "wet lab" validation, forming a rapid iterative closed loop of "preparation - design - validation - optimization," thereby improving the efficiency and success rate of mRNA drug development. Based on the target information provided by YaoTang Biotechnology, JingTai's AI platform will globally optimize multiple objectives such as the expression efficiency, stability, and long-lasting effects of mRNA sequences, and screen the most optimal candidate sequence library. The company expects that the scalable "dry and wet lab" closed-loop iterative platform jointly constructed by both parties will not only serve current specific target projects but can also be expanded to applications in more complex diseases such as solid tumors and central nervous system diseases in the future ### Related Stocks - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [300239.CN](https://longbridge.com/en/quote/300239.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [000863.CN](https://longbridge.com/en/quote/000863.CN.md) ## Related News & Research - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md) - [How AI is changing your investing game](https://longbridge.com/en/news/287144820.md) - [Hippocratic AI Expands Life Sciences Leadership Team as Pharma and Medtech Demand for Voice AI Agents Accelerates](https://longbridge.com/en/news/287107640.md) - [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)